Overview
Ozempic is once-weekly semaglutide, a GLP-1 receptor agonist FDA-approved for type 2 diabetes. Wegovy is the same molecule dosed higher for weight loss. Both slow gastric emptying, blunt appetite, and improve blood sugar.
Treatment
Weekly injection, escalated slowly to minimize GI side effects. Typical weight loss ~15% at max dose. Improves cardiovascular outcomes in diabetes and kidney disease.
Frequently asked
Ozempic vs Wegovy?
Same molecule (semaglutide) — Ozempic FDA-labeled for diabetes, Wegovy for weight loss at higher doses.